A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs

Argoff, Charles E.; Silvershein, Daniel I.
July 2009
Mayo Clinic Proceedings;Jul2009, Vol. 84 Issue 7, p602
Academic Journal
Management of chronic noncancer pain (CNCP) requires a comprehensive assessment of the patient, the Institution of a structured treatment regimen, an ongoing reassessment of the painful condition and its response to therapy, and a continual appraisal of the patient's adherence to treatment. For many patients with CNCP, the analgesic regimen will include opioids. Physicians should consider the available evidence of efficacy, the routes of administration, and the pharmacokinetics and pharmacodynamics of the various formulations as they relate to the temporal characteristics of the patient's pain. When making initial decisions, physicians should decide whether to prescribe a short-acting opioid (SAO) with a relatively quick onset of action and short duration of analgesic activity, along-acting opioid (LAO) with a longer duration of analgesic action but a potentially longer onset of action, or both. Studies suggest that SAOs and LAOs are both effective for most types of CNCP. A review of published studies found no data to suggest that either SAOs or LAOs are generally more efficacious for treating any particular CNCP condition. The LAOs may provide more stable analgesia with less frequent dosing; however, opioid therapy should be tallored to the pain state and the individual patient, and SAOs may be appropriate for some patients with CNCP. MEDLINE and PubMed searches were conducted to locate relevant studies published from January 1975 to April 2008 using the following search terms: opioids, short-acting opioids, long-acting opioids, chronic pain, chronic pain AND opioids, and narcotics. English-only randomized controlled trials and nonrandomized studies were considered.


Related Articles

  • Strategies to optimise propofol-opioid anaesthesia. Lichtenbelt, Bart-Jcin; Mertens, Martijn; Vuyk, Jaap; Lichtenbelt, Bart-Jan // Clinical Pharmacokinetics;2004, Vol. 43 Issue 9, p577 

    Propofol-opioid combinations are widely used in today's anaesthetic practice. Over the past 20-30 years the pharmacology of these agents has been described in increasingly greater detail. Together with novel intravenous administration devices and improved anaesthetic depth monitoring, this has...

  • Cardiotoxicity of Oral Methadone as an Analgesic-recommendations for Safe Use. Guay, David R. P. // Clinical Medicine: Therapeutics;2009, Issue 1, p1073 

    Once used only as third-line therapy in the management of chronic pain states, methadone is now being used as firstand second-line therapy. Most risks and the stigma associated with methadone use have been known for years. Only over the past decade or so have the unique...

  • Experience with Remifentanil in Neonates and Infants. Welzing, Lars; Roth, Bernhard // Drugs;2006, Vol. 66 Issue 10, p1339 

    Remifentanil is a relatively new synthetic opioid, which is not licensed worldwide for neonates and infants. Because of its unique pharmacokinetic properties with a short recovery profile, it could be the ideal opioid for neonates and infants, who are especially sensitive to respiratory...

  • The effects of buprenorphine on fentanyl withdrawal in rats. Bruijnzeel, Adrie W.; Marcinkiewcz, Catherine; Isaac, Shani; Booth, Matthew M.; Dennis, Donn M.; Gold, Mark S. // Psychopharmacology;May2007, Vol. 191 Issue 4, p931 

    Fentanyl is a potent mu-opioid receptor agonist that is widely used for the treatment of severe chronic pain. Discontinuation of fentanyl administration has been shown to induce a negative emotional state. The aim of the present studies was to investigate the effects of the partial mu-opioid...

  • Constipation caused by opioids treated with MTX.  // Hospice Management Advisor;Oct2008, Vol. 13 Issue 10, p118 

    The article provides information on opioid-induced bowel dysfunction (OBD) which is caused by opioids treated with methylnaltrexone (MTX). It states that MTX is a mu receptor antagonist which does not induce withdrawal symptoms in patients undertaking chronic opioid therapy. Pilot trials also...

  • Why Patients Do Not Take Their Opioids. Arnold, Robert // Journal of Palliative Medicine;Oct2004, Vol. 7 Issue 5, p716 

    Presents the factors that contribute to the apprehension of patients towards taking their opioids. Fear of addiction; Opioid toxicity; Tips for assessing patients regarding their use of analgesics.

  • Grundprinzipien der Therapie mit Neuropsychopharmaka. Gründer, G.; Veselinović, T.; Paulzen, M. // Der Nervenarzt;Sep2012, Vol. 83 Issue 9, p1193 

    This review provides the general principles for a rational therapy with psychotropic drugs. It covers the discussion on the basics of the pharmacokinetics (with consideration of drug metabolism and the importance of genetic polymorphisms), pharmacodynamics (drug-receptor interaction, receptor...

  • Dihydrocodeine as an Opioid Analgesic for the Treatment of Moderate to Severe Chronic Pain. Leppert, Wojciech // Current Drug Metabolism;Jul2010, Vol. 11 Issue 6, p494 

    Dihydrocodeine (DHC) is a semi-synthetic analogue of codeine which was formed by the hydrogenation of the double tie in the main chain of the codeine molecule. DHC is used as an analgesic, antitussive and antidiarrhoeal agent; it is also used for the treatment of opioid addiction. Limited data...

  • Methylnaltrexone. Garnock-Jones, Karly P.; McKeage, Kate // Drugs;2010, Vol. 70 Issue 7, p919 

    Methylnaltrexone is a selective m-opioid receptor antagonist that has restricted ability to cross the blood-brain barrier, thus enabling reversal of opioidinduced peripheral effects, such as constipation, without affecting the central effects, such as pain relief. Treatment with subcutaneous...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics